
Venus Remedies, a global pharmaceutical innovator, has obtained marketing authorization for docetaxel in Israel and cytarabine in Colombia. Docetaxel treats various cancers, while cytarabine is effective against leukemia. Israel's $5 billion pharmaceutical market is expected to grow at a 4.2% CAGR until 2026. Venus Remedies expands significantly into Latin America with cytarabine approval in Colombia, the third-largest pharmaceutical market in South America, with a projected 3.1% CAGR until 2026. CEO of Venus Medicine Research Centre expresses commitment to healthcare excellence.
Like
Save
Share